Inotiv, has recently acquired BioReliance Genetox assets as a strategic fit into our portfolio, click here to see press release. Using this as a starting base, Inotiv will offer a Genetic Toxicology Program with a battery of validated genetic toxicology in vitro cell-based assays and in vivo assays to meet ICH, OECD, EFSA, FDA, and EPA guidelines and testing requirements. The program also customizes services to meet clients’ individualized testing needs and provides issue resolution follow-on strategies.

We are currently offering non-GLP studies and are ramping up our GLP services to deliver a full core battery of tests soon. As we continue to add services, please contact us to discuss your needs.